Voiant (USA) and Thirona
(The Netherlands) are pleased to
announce they have entered a global commercial partnership,
combining Voiant's expertise in supporting clinical trials in
pulmonary drug and treatment development with Thirona's expertise
in advanced lung image analysis. Building further on several years
of a fruitful cooperation, the two companies are now formally
joining forces to provide full scope integral services for clinical
trials with AI-powered lung image analysis.
WALTHAM,
Mass. and NIJMEGEN, The
Netherlands, April 24,
2024 /PRNewswire-PRWeb/ -- Voiant (USA) and Thirona (The Netherlands) are pleased to announce they
have entered a global commercial partnership, combining Voiant's
expertise in supporting clinical trials in pulmonary drug and
treatment development with Thirona's expertise in advanced lung
image analysis. Building further on several years of a fruitful
cooperation, the two companies are now formally joining forces to
provide full scope integral services for clinical trials with
AI-powered lung image analysis.
"our integrated platform efficiently meets
comprehensive pulmonary research needs. Together, we offer rapid
and reliable delivery of precise image endpoints for lung diseases"
", says Jim Primerano, CEO at
Voiant.
With AI imaging playing an increasingly important role in
clinical trials, companies recognize the market need for highly
reliable integrated solutions supporting clients in imaging-based
trials. Ensuring a robust quality assurance process along the whole
trial is critical to deliver reliable and accurate outcomes,
minimizing the risk of trial failure and saving on developmental
costs.
"With Voiant's network of over 400 certified sites and Thirona's
robust algorithm suites, our integrated platform efficiently meets
comprehensive pulmonary research needs. Together, we offer rapid
and reliable delivery of precise image endpoints for lung
diseases", says Jim Primerano, CEO
at Voiant.
"Imaging offers enormous new possibilities in drug and treatment
development, but it requires solid experience to do it right and
efficiently. Voiant's operational expertise and capabilities in
managing complex imaging workflows form a perfect match with our
competences in AI-powered lung image analysis." says Eva van
Rikxoort, founder and CEO of Thirona.
About Voiant
Voiant is an industry leading clinical trial imaging solution
provider with unparalleled scientific and clinical domain
expertise, providing biopharmaceutical companies with high-speed
delivery of quality clinical endpoint data. Voiant's fully
configurable, highly scalable imaging platform can be accessed
anywhere, on any device, enabling sites, readers and sponsors to
work together within the same system, supporting the entire
clinical imaging endpoint data delivery from images upload to
queries management, data analysis and reporting. Over the last 30
years, Voiant has interpreted over half a billion images from
hundreds of global clinical trials, aiding numerous
biopharmaceutical companies bringing new treatments to patients
across oncology, respiratory, ophthalmology, cardiovascular and
gastrointestinal disease domains.
Additional information is available at
www.voiantclinical.com.
Media contact Voiant: info@voiantclinical.com
About Thirona
To help make personalized treatment in lung diseases accessible
for everyone, Thirona leverages artificial intelligence to deliver
high-precision advanced lung image analysis and expertise-based
services for MedTech, pharmaceutical and CRO companies. Thirona
also partners with research institutions and medical companies to
enable breakthroughs in precision medicine for the personalized
treatment of pulmonary diseases. Founded by Eva van Rikxoort
in 2014, the company has established a proven track record of
translating technology into certified clinical end-products through
co-innovation with leading MedTech companies.
Thirona's state-of-the-art lung quantification platform LungQ™
consists of a comprehensive portfolio of robust high-performance
AI-based algorithms trained on a wide range of disease-specific
datasets, delivering consistent and reproducible results. The
unique, scalable platform powers exploratory research studies as
well as large multi-site clinical trials and has been cited in over
200 publications.
For more information visit: thirona.eu
Contact: mediarelations@thirona.eu
Media Contact
Stephane Deleger, Voiant, 1
4159631773, sdeleger@voiantclinical.com,
www.voiantclinical.com
View original content to download
multimedia:https://www.prweb.com/releases/voiant-and-thirona-announce-commercial-partnership-for-full-scope-services-in-imaging-based-clinical-trials-for-pulmonary-diseases-302125566.html
SOURCE Voiant